Results 171 to 180 of about 2,002,821 (297)

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Empowering Saudi pharmacy students: A nudge-based intervention for improved health behaviors. [PDF]

Saudi Med J
Alzahrani FM, Bojan BS, Fadil HA.
europepmc   +1 more source

Health Behavior [PDF]

American Journal of Public Health and the Nations Health, 1928
openaire   +1 more source

Adverse Childhood Experiences, Disability and Health-Risk Behaviors [PDF]

, 2013
Schussler-Fiorenza Rose, Sophia Miryam, MD, PhD
core   +1 more source

Prevalence and Perception of risky health behaviors among construction workers [PDF]

, 2017
Arezes, Arias, Armour, Arndt, Barbeau, Barbeau, Barnes, Boal, Brewer, Carter, Claessen, Coups, Dement, Dong, Dong, Dutra, Evanoff, Fan, Field, Graber, Gu, Gu, Hakes, Hallowell, Ham, Heatherton, Hecht, Hjermann, Kaskutas, Knutsson, Lee, Lipscomb, Luckhaupt, Nigg, Okechukwu, Reinau, Robinson, Rodriguez-Garzon, Smith   +38 more
core   +2 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Natural environments and suicide

The Lancet Planetary Health, 2018
Shu-Sen Chang, David Gunnell
doaj   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Health behaviors, and beliefs about health behaviors and cancer risk, among US cancer survivors: a HINTS-SEER study. [PDF]

Cancer Surviv Res Care
Van Blarigan EL, Li S, Vanderpool RC, Shariff-Marco S, Nash SH, McKinley M, Everson NS, Meisner ALW, Gorzelitz J, Gomez SL, DeRouen MC.   +10 more
europepmc   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source